Ingenol derivative - LEO Pharma
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator LEO Pharma
- Class Diterpenes; Ingenols; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Actinic keratosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Actinic keratosis in Australia (Topical, Gel)
- 31 Mar 2013 LEO Pharma completes a phase I trial in Actinic keratosis in Australia (NCT01703078)
- 03 Feb 2013 LEO Pharma completes enrolment in its phase I trial for Actinic keratosis in Australia (NCT01703078)